Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

At their Annual Meeting 13 Sept, the Trustees of the Royal Society of Tropical Medicine and Hygiene (RSTMH) awarded MORU’s Dr Direk Limmathurotsakul its Emerging Leaders Award.

Direk Limmathurotsakul

Awarded annually, the RSTMH Emerging Leaders Award recognises significant contributions in leadership and service, including mentoring and other forms of capacity-building, to the fields of tropical medicine and global health by early-career investigators based in low and middle-income countries.

Based in Bangkok and Head of Microbiology at MORU, Direk is an Assistant Professor at the Faculty of Tropical Medicine at Mahidol University in Thailand and a Wellcome Trust Intermediate Fellow in Public Health and Tropical Medicine.

“I would like to thank my colleagues Susanna Dunachie and Nick Day who nominated me and presented the citation at the meeting. I very much appreciate their kindness and support,” said Direk at the Awards ceremony.

Recognised as a world expert on melioidosis, an infectious disease caused by Burkholderia pseudomallei, Direk has published more than 100 publications on melioidosis over the past decade and led a series of laboratory and clinical studies demonstrating for the first time that ingestion and inhalation are important infection routes for melioidosis in northeast Thailand.

Direk also developed the first evidence-based guidelines for the prevention of melioidosis for people living in endemic areas and recently published a landmark melioidosis paper, estimating the global burden of melioidosis, in Nature Microbiology 2016. He mapped all documented human and animal cases, and the presence of environmental B. pseudomallei, and combined this in a formal modelling to estimate the global burden of melioidosis. He estimated there to be 165,000 human melioidosis cases per year worldwide, of which 89,000 die.

A lead researcher in antimicrobial resistance in Southeast Asia, Direk’s on-going research includes antibiotic use in animals, estimating the burden of antimicrobial-resistant infections in Southeast Asia, and identifying where resources are most needed to fight effectively against antimicrobial resistance in low and middle-income countries.

Similar stories

Phase II Malaria vaccine trial begins in Thailand

The Mahidol Oxford Tropical Medicine Research Unit (MORU) has begun a Phase II trial to demonstrate that R21/matrix M is well-tolerated and immunogenic when administered with the antimalarial drug combination.

Pilot study detects diverse DNA in ingredients of falsified tablets

A recent multidisciplinary pilot study, originating from LOMWRU and the Medicine Quality Research Group of IDDO and MORU, investigated whether bacterial, plant, fungal and animal DNA in the ingredients and from the environment (eDNA) could be detected from falsified (aka counterfeit) tablets.

Ricardo Aguas awarded Associate Professorship

We are delighted to announce that Ricardo Aguas has been awarded the Associate Professor title, in recognition of his achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine.

COPCOV investigators meet, and prepare to submit for publication

On 15-16 Dec, COPCOV investigators from around the world met in Bangkok to review study results and plan next steps. Led by co-PIs Prof Sir Nick White and Dr Will Schilling, and funded by the Wellcome Trust, the MORU-led COPCOV ( Chloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting) is the world’s largest multinational trial of COVID-19 prevention.

Researchers call for antimicrobial resistance surveillance to be improved

The number of studies reporting antimicrobial resistance (AMR) data has increased in Africa, South and South East Asia according to new research in the International Journal of Infectious Diseases.

Are we getting tafenoquine dosing right?

Researchers analysing clinical trial data for the new antimalarial drug tafenoquine find that higher doses are needed to cure reliably vivax malaria infection.